NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

Conditions: Triple Negative Breast Cancer Interventions: Drug: Sacituzumab govitecan; Drug: Pembrolizumab Sponsors: West German Study Group; Gilead Sciences; Merck Sharp& Dohme LLC Not yet recruiting

https://clinicaltrials.gov/study/NCT06081244

Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials